ReviewJournal of clinical medicine2019
History of Inflammatory Bowel Diseases.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Exploring the novel ameliorative effect of date palm pollen extract in inflammatory bowel disease.Inflammopharmacology · 2026Article
- The Gut Mycobiome in Inflammatory Bowel Disease: ReframingJournal of fungi (Basel, Switzerland) · 2026Review
- Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study.Journal of clinical medicine · 2025Article
- Medical gaslighting as a threat to beneficence and patient autonomy: a qualitative study.BMC medical ethics · 2025Article
- The comparison of antioxidant and anti-inflammatory potency of native probiotics and paraprobiotics in DSS-induced colitis mice with a normal diet.Genes & nutrition · 2025Article
- Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease.World journal of nephrology · 2025Article
- Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study.Journal of clinical medicine · 2025Article
- Benchmarking in inflammatory bowel disease: lessons from Australia and New Zealand.Journal of the Canadian Association of Gastroenterology · 2025Article
- The importance of growth differentiation factor 15 and interleukin 6 serum levels in inflammatory bowel diseases.Journal of physiology and biochemistry · 2025Article
- Adiponectin and HMW Oligomers in Relation to Inflammatory Markers in Crohn's Disease Patients.Biomedicines · 2025Article
- A review of inflammatory bowel diseases in humans and pets: treatment strategies.Veterinary research forum : an international quarterly journal · 2025Review
- Macrophage Metabolic Reprogramming in Inflammatory Bowel Diseases: From Pathogenesis to Therapy.Journal of inflammation research · 2025Review
- Bile acid receptors regulate the role of intestinal macrophages in inflammatory bowel disease.Frontiers in immunology · 2025Review
- Interprofessional approach to personalized medication management and therapy optimization in IBD care.Frontiers in medicine · 2025Article
- Article
- Secondary amyloidosis in inflammatory bowel disease patients: findings from three tertiary medical centers.Clinical journal of gastroenterology · 2024Article
- Medication-related burden among Iraqi patients with ulcerative colitis: a cross-sectional study.Journal of medicine and life · 2024Article
- Colon targeting in rats, dogs and IBD patients with species-independent film coatings.International journal of pharmaceutics: X · 2024Article
- Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study.Biomedicines · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal mucosa and unknown etiology. In this review, we identified three main eras in the IBD history. Between the 19th and the 20th century, the primary task had been the definition of the diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis. In the 20th century, an intense and prolific therapeutic research prevailed, culminating in the introduction of biological drugs in the clinical setting. Since the beginning of the 21st century, traditional definition criteria have been challenged by holistic criteria in an effort to seek a still unattained cure. Centuries of worldwide efforts on IBD etiology and therapy search have culminated in this novel strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.